Author Archives: Aisha I Abdullah PhD

Phase 3 Trial Testing MT-7117 for EPP, XLP Now Enrolling at 3 US Sites

A Phase 3 clinical trial of MT-7117 (dersimelagon), Mitsubishi Tanabe Pharma‘s experimental treatment for erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), is now enrolling participants at three sites in the U.S. The three locations are in Winston-Salem, N.C., Columbus, Ohio, and Boston. More information on the trial sites, including…